Recent Research Analysts’ Ratings Changes for Ascendis Pharma A/S (ASND)

Several brokerages have updated their recommendations and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) in the last few weeks:

• 11/4/2024 – Ascendis Pharma A/S was upgraded by analysts at Wedbush to a “strong-buy” rating.
• 11/4/2024 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
• 10/23/2024 – Ascendis Pharma A/S had its price target lowered by analysts at JPMorgan Chase & Co. from $180.00 to $174.00. They now have an “overweight” rating on the stock.
• 10/21/2024 – Ascendis Pharma A/S had its price target raised by analysts at TD Cowen from $157.00 to $160.00. They now have a “buy” rating on the stock.
• 9/23/2024 – Ascendis Pharma A/S had its price target raised by analysts at Bank of America Co. from $175.00 to $191.00. They now have a “buy” rating on the stock.
• 9/17/2024 – Ascendis Pharma A/S had its price target raised by analysts at Wells Fargo & Company from $264.00 to $289.00. They now have an “overweight” rating on the stock.
• 9/17/2024 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $190.00 price target on the stock, up previously from $180.00.
• 9/17/2024 – Ascendis Pharma A/S had its price target raised by analysts at Evercore ISI from $191.00 to $205.00. They now have an “outperform” rating on the stock.
• 9/17/2024 – Ascendis Pharma A/S had its price target raised by analysts at Citigroup Inc. from $178.00 to $207.00. They now have a “buy” rating on the stock.
• 9/17/2024 – Ascendis Pharma A/S had its price target raised by analysts at The Goldman Sachs Group, Inc. from $180.00 to $200.00. They now have a “buy” rating on the stock.
• 9/16/2024 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.

Ascendis Pharma A/S Trading Down 0.7 %

NASDAQ:ASND traded down $0.86 during mid-day trading on Wednesday, reaching $127.27. 21,947 shares of the stock were exchanged, compared to its average volume of 441,980. The business has a fifty day moving average price of $132.96 and a 200 day moving average price of $133.37. The firm has a market capitalization of $7.72 billion, a PE ratio of -13.67 and a beta of 0.66. Ascendis Pharma A/S has a 1-year low of $86.54 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.24 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares during the last quarter. Searle & CO. bought a new stake in Ascendis Pharma A/S in the second quarter worth $205,000. Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares in the last quarter. Finally, Pursue Wealth Partners LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth about $217,000.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.